Main Article Content
hydroxyurea, treatment, sickle cell anemia, clinical management, hemoglobinopathies, prognosis.
2. Rosenthal F, Wislicki L, Koller L. Über die beziehungen von schwerstenblutgiftenzuabbauprodukten des eiweisses: einbeitragzumentstehungmechanismus der pernizosenanemie. KlinWochenschr 1928; 7:972-7.
3. Stearns B, Losee KA, Bernstein J. Hydroxyurea: a new type of potential antitumor agent. J Med Chem 1963; 6:201.
4. Fishbein WN, Carbone PP, Freireich EJ, et al. Clinical trials of hydroxyurea in patients with cancer and leukemia. Clin Pharmacol Ther 1964; 5:574-80.
5. Becloff GL. Pharmacological, metabolic and clinical experience with hydroxyurea. Clin Trials J 1967; 4:873-83.
6. Kennedy BJ. Hydroxyurea therapy in chronic myelogenous leukemia.Cancer 1972; 29:1052-6.
7. Tefferi A, Pardanani A. Myeloproliferative neoplasms. A contemporary review. JAMA Oncol 2015; 1:97-105.
8. Cortelazzo S, Finazzi G, Specchia G, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995; 332:1132-6.
9. Fruchtman SM, Mack K, Kaplan ME, et al. From efficacy to safety: a Polycytemia Vera Study Group report on hydroxyurea in patients with polycytemia vera. Semin Hematol 1997; 34:17-23.
10. Tefferi A. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014; 89:915-25.
11. Leavell UW, Yarbro JW. Hydroxyurea. A new treatment for psoriasis. Arch Dermatol 1970; 102:144-50.
12. Herrick JB. Peculiar elongated and sickle-shaped red blood corpuscules in a case of severe anemia. Arch Intern Med 1910; 6:517-21.
13. Pauling L, ItanoHA.Sickle cell anemia, a molecular disease. Science 1949; 109:443.
14. Allison AC.The distribution of the sickle-cell trait in East Africa and elsewhere, and its apparent relationship to the incidence of subtertianmalaria.Trans R SocTrop Med Hyg 1954; 48:312-8.
15. Taylor SM, Parobeck CM, Fairhurst RM. Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:457-68.
16. Ingram VM. A specific chemical difference between the globins of normal human and sickle-cell anaemiahaemoglobin.Nature 1956; 178:792-4.
17. Schmidt RM, Brosious EM. Evaluation of proficiency in the performance of tests for abnormal hemoglobins.Am J ClinPathol 1974; 62:664-9.
18. Scott RB. Health care priority and sickle cell anemia. JAMA 1970; 214:731-4.
19. Benson JM, Therrell BL Jr. History and current status of newborn screening for hemoglobinopathies. SeminPerinatol 2010; 34: 134-44.
20. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood 2010; 115:3447-52.
21. Naik RP, Derebail VK, Grams ME, et al. Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans. JAMA 2014; 312:2115-25.
22. Auer PL, Johnsen JM, Johnson AD, et al. Imputation of exome sequence variants into population-based samples and blood-cell-trait associated loci in African Americans: NHLBI GO Exome Sequencing Project. Am J Hum Genet 2012; 91:794-808.
23. Platt OS, Orkin SH, Dover G, et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984 ; 74 :652-6.
24. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease: rates and risk factors. N Engl J Med 1991; 325:11-6.
25. Castro O, Brambilla DJ, Thorington BD, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors.The Cooperative Study of Sickle Cell Disease.Blood 1994; 84:643-9.
26. Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med 2008; 359:2254-65.
27. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med 1994; 330:1639-44.
28. Charache S, Terrin ML, Moore RD, et al. Effects of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995; 332:1317-22.
29. Segal JB, Strouse JJ, Beach MC, et al. Hydroxyurea for the treatment of sickle cell disease.Evid Rep Technol Assess 2008; 165:1-95.
30. Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med 2008; 148:932-8.
31. Franco RS, Yasin Z, Palascak MB, et al. The effect of fetal hemoglobin on the survival characteristics of sickle cells.Blood 2006; 108:1073-6.
32. Platt OS.Hydroxyurea for the treatmet of sickle cell anemia. N Engl J Med 2008; 358:1362-9.
33. Cokic VP, Smith RD, Beleslin-Cokic BB, et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylylcyclase. J Clin Invest 2003; 111:231-9.
34. Letvin NL, Linch DC, Beardsley GP, McIntyre KW, Nathan DG. Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. N Engl J Med 1984; 310:869-73.
35. Wong TE, Brandow AM, Lim W, Lottenberg R. Update on the use of hydroxyurea therapy in sickle cell disease. Blood 2014; 124:3850-7.
36. Buckner TW, Ataga KI. Does hydroxyurea prevent pulmonary complications of sickle cell disease? Hematology (Educational Sessions of the American Society of Hematology) 2014; 432-7.
37. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamine in very young children with sickle-cell anaemia: a multicentre, randomized, controlled trial (BABY HUG). Lancet 2011; 377:1663-72.
38. Ware RE, Helms RW. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood 2012; 119:3925-32.
39. Jain DL, Sarathi V, Desai S, et al. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin 2012; 36:323-32.
40. Wang W, Brugnara C, Snyder C, et al. The effects of hydroxycarbamine and magnesium on haemoglobin SC disease: results of the multicentre CHAMPS trial. Br J Haematol 2011; 152:771-6.
41. Alvarez O, Yovetich NA, Scott JP, et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. Am J Hematol 2013; 88:932-8.
42. Lebensburger JD, Miller ST, Howard TH, et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatr Blood Cancer 2012; 59:675-8.
43. Thornburg CD, Files BA, Luo Z, et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood 2012; 120:4304-10.
44. Ali SB, Moosang M, King L, et al. Stroke recurrence in children with sickle cell disease treated with hydroxyurea following first clinical stroke. Am J Hematol 2011; 86:846-50.
45. Gilmore A, Cho G, Howard J, et al. Feasibility and benefit of hydroxycarbamide as a long-term treatment for sickle cell disease patients: results from the North West London Sickle Cell Disease Registry. Am J Hematol 2011; 86:958-61.
46. Italia K, Jain D, Gattani S, et al. Hydroxyurea in sickle cell disease – a study of clinic-pharmacological efficacy in the Indian haplotype. Blood Cells Mol Dis 2009; 42:25-31.
47. Lobo CL, Pinto JF, Nascimento EM, et al.The effect of hydroxycarbamine therapy on survival of children with sickle cell disease. Br J Haematol 2013; 161:852-60.
48. Nzouakou R, Bachir D, Lavaud A, et al. Clinical follow-up of hydroxyurea-treated adults with sickle cell disease. ActaHaematol 2011; 125:145-52.
49. Patel DK, Mashon RS, Patel S, et al. Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India. Hemoglobin 2012; 36:409-20.
50. Rigano P, Pecoraro A, Calvaruso G, et al. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians. Am J Hematol 2013; 88:E261-4.
51. Sharef SW, Al-Hajri M, Beshlawi I, et al. Optimizing hydroxyurea use in children with sickle cell disease: low dose regimen is effective. Eur J Haematol 2013; 90:519-24.
52. Singh H, Dulhani N, Kumar BN, et al. Effective control of sickle cell disease with hydroxyurea therapy. Indian J Pharmacol 2010; 42:32-5.
53. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol 2010; 85:403-8.
54. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 2010; 115:2354-63.
55. Gulbis B, Haberman D, Dufour D, et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. Blood 2005; 105:2685-90.
56. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood 2005; 106:2269-75.
57. Jain DL, Apte M, Colah R, et al. Efficacy of fixed low dose hydroxyurea in Indian children with sickle cell anemia: a single centre experience. Indian Pediatr 2013; 50:929-33.
58. Koren A, Segal-Kupershmit D, Zalman L, et al. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell beta-thalassemia. Pediatr Hematol Oncol 1999; 16:221-32.
59. Olivieri NF, VichinskyEP. Hydroxyurea in children with sickle cell disease: impact on splenic function and compliance with therapy. J Pediatr Hematol Oncol 1998; 20:26-31.
60. Silva-Pinto AC, Angulo IL, Brunetta DM, et al. Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil. Sao Paulo Med J 2013; 131:238-43.
61. Desai PC, May RC, Jones SK, et al. Longitudinal study of echocardiography-derived tricuspid regurgitant jet velocity in sickle cell disease. Br J Haematol 2013; 162:836-41.
62. Gordeuk VR, Campbell A, Rana S, et al. Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease. Blood 2009; 114:4639-44.
63. Pashankar FD, Carbonella J, Bazzy-Asaad A, et al. Prevalence and risk factors of elevated pulmonary artery pressures in children with sickle cell disease. Pediatrics 2008; 121:777-82.
64. Voskaridou E, Tsetsos G, Tsoutsias A, et al. Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations. Haematologica 2007; 92:738-43.
65. Fonseca GH, Souza R, Salemi VM, et al. Pulmonary hypertension diagnosed by right heart catheterization in sickle cell disease. EurRespir J 2012; 39:112-8.
66. Parent F, Bachir D, Inamo J, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 2011; 365:44-53.
67. Dahoui HA, Hayek MN, Nietert PJ, et al. Pulmonary hypertension in children and young adults with sickle cell disease: evidence for familial clustering. Pediatr Blood Cancer 2010; 54:398-402.
68. Ataga KI, Moore CG, Jones S, et al. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol 2006; 134:109-15.
69. De Castro LM, Jonassaint JC, Graham FL, et al. Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. Am J Hematol 2008; 83:19-25.
70. Ware RE, Zimmerman SA, Sylvestre PB, et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr 2004; 145:346-52.
71. Chou ST, Jackson T, Vege S, et al. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 2013; 122:1062-71.
72. Zimmerman SA, Schultz WH, Burgett S, et al. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood 2007; 110:1043-7.
73. Hankins JS, McCarville MB, Rankine-Mullings A, et al. Prevention of conversion to abnormal TCD with hydroxyurea in sickle cell anemia: A phase III international randomized clinical trial. Am J Hematol 2015; 90:1099-105.
74. Aygun B, Mortier NA, Kesler K, et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. Br J Haematol 2015; 169:262-6.
75. Alvarez O, Miller ST, Wang WC, et al. Effect of hydroxyurea treatment on renal function parameters: results from the multicenter placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatr Blood Cancer 2012; 59:668-74.
76. Hankins JS, Helton KJ, McCarville MB, et al. Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatr Blood Cancer 2008; 50:293-7.
77. Aygun B, Mortier NA, Smeltzer MP, et al. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia. Am J Hematol 2013; 88:116-9.
78. Estepp JH, Smeltzer MP, Wang WC, et al. Protection from sickle cell retinopathy is associated with elevated HbF levels and hydroxycarbamine use in children. Br J Haematol 2013; 161:402-5.
79. McKie KT, Hanevold CD, Hernandez C, et al. Prevalence, prevention, and treatment of microalbuminuria and proteinuria in children with sickle cell disease. J PediatrHematolOncol 2007; 29:140-4.
80. Mulaku M, Opiyo N, Karumbi J, et al. Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries. Arch Dis Child 2013; 98:908-14.
81. Ware RE, Despotovic JM, Mortier NA, et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood 2011; 118:4985-91.
82. Charache S, Dover GJ, Moore RD, et al. Hydroxyurea. Effects on hemoglobin F production in patients with sickle cell anemia.Blood 1992; 79:2555-65.
83. Ware RE. Optimizing hydroxyurea therapy for sickle cell anemia. Hematology (Educational Sessions of the American Society of Hematology) 2015; 436-43.
84. Savage WJ, Buchanan GR, Yawn BP, et al. Evidence gaps in the management of sickle cell disease: a summary of needed research. Am J Hematol 2015; 90:273-5.
85. Flanagan JM, Howard TA, Mortier N, et al. Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. Mutat Res 2010; 698:38-42.
86. Ballas SK, McCarthy WF, Guo N, et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. J Natl Med Assoc 2009; 101:1046-51.
87. Elion J, Berg PE, Lapoumeroulie C, et al. DNA sequencevariation in a negative control region 5’ to the beta-globin gene correlates with the phenotypic expression of the beta S mutation. Blood 1992; 79:787-92.
88. Lorey FW, Arnopp J, Cunningham GC. Distribution of hemoglobinopathy variants by ethnicity in a multiethnic state.Genet Epidemiol 1996; 13:501-12.
89. Treadwell MJ, McClough L, Vichinsky E. Using qualitative and quantitative strategies to evaluate knowledge and perceptions about sickle cell disease and sickle cell trait. J Natl Med Assoc 2006; 98:704-10.
90. Kavanagh PL, Wang CJ, Therrell BL, et al. Communication of positive newborn screening results for sickle cell disease and sickle cell trait: variation across states. Am J Med Genet C Semin Med Genet 2008; 148C:15-22.
91. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood 2010; 115:4331-6.
92. Piel FB, Hay SI, Gupta S, et al. Global burden of sickle cell anaemia in children under five, 2010-2050: modeling based on demographics, excess mortality, and interventions. PLoS Med 2013; 10:e1001484.
93. World Health Organization. Sickle-cell disease: a strategy for the WHO African Region. Report AFR/RC60/8. Geneva, Switzerland: World Health Organization; 2010.
94. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014; 12:1033-48.
95. Cunningham-Myrie C, Abdulkadri A, Waugh A, et al. Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: a cost effectiveness analysis. Pediatr Blood Cancer 2015; 62:1862-4.
96. Steiner CA, Miller JL. Sickle cell disease patients in U.S. hospitals, 2004.Statistical brief. No.21. Rockville, Md: Agency for Healthcare Research and Quality, December 2006.
97. Moore RD, Charache S, Terrin ML, et al. Cost-effectiveness of hydroxyurea in sickle cell anemia. Am J Hematol 2000; 64:26-31.
98. Telen MJ. Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. Blood 2016; 127:810-9.
99. Atweh GF, Sutton M, Nassif I, et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood 1999; 93:1790-7.
100. Saunthararajah Y, Molokie R, Saraf S, et al. Clinical effectiveness of decitabine in severe sickle cell disease. Br J Haematol 2008; 141:126-9.
101. Dos Santos JL, Lanaro C, Lima LM, et al. Design, synthesis, and pharmacological evaluation of novel hydrid compounds to treat sickle cell disease symptoms. J Med Chem 2011; 54:5811-9.
102. Meiler SE, Wade M, Kutlar F, et al. Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice. Blood 2011; 118:248-58.
103. Fard AD, Hosseini SA, Shahjahani M, et al. Evaluation of novel fetal hemoglobin inducer drugs in treatment of ?-hemoglobinopathy disorders. Int J Hematol Oncol Stem Cell Res 2013; 7:47-54.
104. Ataga KI, Stocker J. Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia. Expert Opin Investig Drugs 2009; 18:231-9.
105. Misra H, Lickliter J, Kazo F, Abuchowski A. PEGylated carboxyhemoglobin bovine (SANGUINATE): result of a phase I clinical trial. Artif Organs 2014; 38:702-7.
106. Chang J, Patton JT, Sarkar A, et al. GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice. Blood 2010; 116:1779-86.
107. Mandarino D, Kawar Z, Alvarez R, et al. Placebo-controlled, double-blind, first-in-human, ascending single dose, healthy subject study of intravenous-administered SelG1, a humanized anti-P-selectin antibody in development for sickle cell disease. Blood 2013; 122:abstract 970.
108. Batchvarova M, Shan S, Zennadi R, et al. Sevuparin reduces adhesion of both sickle red cells and leukocytes to endothelial cells in vitro and inhibits vaso-occlusion in vivo. Blood 2013;122:abstract 182.
109. Qari MH, Aljaouni SK, Alardawi MS, et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thromb Haemost 2007; 98:392-6.
110. De Castro LM, Zennadi R, Jonassaint JC, et al. Effect of propranolol as anti-adhesive therapy in sickle cell disease. Clin Transl Sci 2012; 5:437-44.
111. Zennadi R. MEK inhibitors, novel anti-adhesive molecules, reduce sickle red blood cell adhesion in vitro and in vivo, and vasoocclusion in vivo. PLoS One 2014; 9:e110306.
112. Cheung AT, Chan MS, Ramanujam S, et al. Effects of poloxamer 188 treatment on sickle cell vaso-occlusive crisis: computer-assisted intravital microscopy study. J Investig Med 2004; 52:402-6.
113. Field JJ, Lin G, Okam MM, et al. Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist ragadenoson. Blood 2013; 121:3329-34.
114. Field JJ, Ataga KI, Majerus E, et al. A phase I single ascending dose study of NKTT120 in stable adult sickle cell patients. Blood 2013; 122:abstract 977.
115. Knight-Perry J, DeBaun MR, Strunk RC, Field JJ. Leukotriene pathway in sickle cell disease: a potential target for directed therapy. Expert Rev Hematol 2009; 2:57-68.
116. Chang J, Shi PA, Chiang EY, Frenette PS. Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. Blood 2008; 111:915-23.
117. Hoppe C, Kuypers F, Larkin S, et al. A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. Br J Haematol 2011; 153:655-63.
118. Bhatia M, Walters MC. Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future. Bone Marrow Transplant 2008; 41:109-17.